Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus

Overview

Journal Clin Appl Thromb Hemost

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 26

PMID 39587795

Authors

Shosaku Nomura

Takehito Taniura

Jun Ichikawa

Ayako Iwama

Tomoki Ito

Affiliations

Soon will be listed here.

Abstract

We measured high mobility group box 1 protein (HMGB1) and platelet-derived microparticles (PDMP) in blood samples from patients with untreated type 2 diabetes mellitus (T2DM). We examined the effects of a combination of sodium/glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Multiple regression analysis of HMGB1 was conducted on data from 252 patients in our previously reported T2DM-related clinical study. The results revealed significant correlations between HMGB1 and PDMP, soluble CD40 ligand, plasminogen activator inhibitor-1, and soluble E-selectin in multivariate analysis. Based on the HMGB1 levels before treatment with combination, 46 T2DM patients in the study were classified into two groups, high and low. The high HMGB1 group showed a significantly lower adiponectin level and higher PDMP production than the low HMGB1 group. T2DM risk significantly and positively correlated with HMGB1 and PDMPs. HMGB1-induced PDMP production was simulated using healthy platelets. Furthermore, The combination of a SGLT2 inhibitor and a DPP-4 inhibitor significantly reduced HMGB1 and PDMP levels. These results suggest that in addition to abnormal glucose metabolism, HMGB1-dependent PDMP production and the resulting development of atherosclerosis are also a concern in patients with T2DM.

References

Nomura S, Taniura T, Shouzu A, Omoto S, Suzuki M, Okuda Y . Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study). Vasc Health Risk Manag. 2018; 14:225-232. PMC: 6151091. DOI: 10.2147/VHRM.S171143. View

Yu Y, Tang D, Kang R . Oxidative stress-mediated HMGB1 biology. Front Physiol. 2015; 6:93. PMC: 4387954. DOI: 10.3389/fphys.2015.00093. View

Abdul-Ghani M, Norton L, DeFronzo R . Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011; 32(4):515-31. DOI: 10.1210/er.2010-0029. View

Beckman J, Creager M, Libby P . Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287(19):2570-81. DOI: 10.1001/jama.287.19.2570. View

Lee N, Heo Y, Choi S, Jeon J, Han S, Kim D . Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways. J Immunol Res. 2021; 2021:9944880. PMC: 8192181. DOI: 10.1155/2021/9944880. View

Brown E, Heerspink H, Cuthbertson D, Wilding J . SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021; 398(10296):262-276. DOI: 10.1016/S0140-6736(21)00536-5. View

Campbell J, Newgard C . Mechanisms controlling pancreatic islet cell function in insulin secretion. Nat Rev Mol Cell Biol. 2021; 22(2):142-158. PMC: 8115730. DOI: 10.1038/s41580-020-00317-7. View

Zhang C, Liu X, Jin S, Chen Y, Guo R . Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022; 21(1):47. PMC: 8840702. DOI: 10.1186/s12943-022-01530-y. View

Dixon S, Lemberg K, Lamprecht M, Skouta R, Zaitsev E, Gleason C . Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149(5):1060-72. PMC: 3367386. DOI: 10.1016/j.cell.2012.03.042. View

10.

Okuda Y, Omoto S, Taniura T, Shouzu A, Nomura S . Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis. Int J Gen Med. 2016; 9:65-71. PMC: 4835142. DOI: 10.2147/IJGM.S102070. View

11.

Taylor R . Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013; 36(4):1047-55. PMC: 3609491. DOI: 10.2337/dc12-1805. View

12.

He J, Li Z, Xia P, Shi A, FuChen X, Zhang J . Ferroptosis and ferritinophagy in diabetes complications. Mol Metab. 2022; 60:101470. PMC: 8980341. DOI: 10.1016/j.molmet.2022.101470. View

13.

Hudish L, Reusch J, Sussel L . β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. J Clin Invest. 2019; 129(10):4001-4008. PMC: 6763241. DOI: 10.1172/JCI129188. View

14.

Li D, Jiang C, Mei G, Zhao Y, Chen L, Liu J . Quercetin Alleviates Ferroptosis of Pancreatic β Cells in Type 2 Diabetes. Nutrients. 2020; 12(10). PMC: 7600916. DOI: 10.3390/nu12102954. View

15.

Nomura S . Extracellular vesicles and blood diseases. Int J Hematol. 2017; 105(4):392-405. DOI: 10.1007/s12185-017-2180-x. View

16.

Hansson G, Libby P . The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6(7):508-19. DOI: 10.1038/nri1882. View

17.

Nomura S, Tandon N, Nakamura T, Cone J, Fukuhara S, Kambayashi J . High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis. 2001; 158(2):277-87. DOI: 10.1016/s0021-9150(01)00433-6. View

18.

Dale G . Procoagulant Platelets: Further Details but Many More Questions. Arterioscler Thromb Vasc Biol. 2017; 37(9):1596-1597. DOI: 10.1161/ATVBAHA.117.309847. View

19.

Wu Y, Sun Y, Wu Y, Zhang K, Chen Y . Predictive value of ferroptosis-related biomarkers for diabetic kidney disease: a prospective observational study. Acta Diabetol. 2023; 60(4):507-516. PMC: 10033569. DOI: 10.1007/s00592-022-02028-1. View

20.

Zhang X, Zhao L, Jin R, Li M, Li M, Li R . CRISPR/Cas9-Mediated α-ENaC Knockout in a Murine Pancreatic β-Cell Line. Front Genet. 2021; 12:664799. PMC: 8047203. DOI: 10.3389/fgene.2021.664799. View